Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anterix (ATEX) EBT (2016 - 2025)

Anterix filings provide 13 years of EBT readings, the most recent being -$8.7 million for Q4 2025.

  • On a quarterly basis, EBT fell 215.74% to -$8.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $85.2 million, a 394.8% increase, with the full-year FY2025 number at -$9.5 million, down 26.15% from a year prior.
  • EBT hit -$8.7 million in Q4 2025 for Anterix, down from $61.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $61.1 million in Q3 2025 to a low of -$14.3 million in Q2 2024.
  • Median EBT over the past 5 years was -$8.2 million (2022), compared with a mean of -$219200.0.
  • Biggest five-year swings in EBT: crashed 561.22% in 2024 and later surged 587.03% in 2025.
  • Anterix's EBT stood at -$12.3 million in 2021, then soared by 36.52% to -$7.8 million in 2022, then soared by 121.33% to $1.7 million in 2023, then skyrocketed by 348.74% to $7.5 million in 2024, then plummeted by 215.74% to -$8.7 million in 2025.
  • The last three reported values for EBT were -$8.7 million (Q4 2025), $61.1 million (Q3 2025), and $22.9 million (Q2 2025) per Business Quant data.